SLATTERY JOSEPH P — SEC insider filings
SEC reporting owner CIK 1246530. 32 insider filings on record with FilingPulse; latest filed 2026-11-10.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2020-12-09 to 2026-11-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 5 filings — 26,900 shares, $217,016 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 10,400 shares, $352,560 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 66.
- Largest priced transaction: sale of 5,200 shares @ $46.00 ($239,200) in Replimune Group, Inc., filed 2020-12-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | Director | 8 | — | 2 legs · 10,400 sh · $352,560 | 8 |
| ImageneBio, Inc. (IMA) | Director | 3 | 1 leg · 16,000 sh · $95,840 | — | 2 |
| CVRx, Inc. (CVRX) | Director | 14 | 3 legs · 8,500 sh · $71,741 | — | 44 |
| Morphic Holding, Inc. (MORF) | Director | 7 | 1 leg · 2,400 sh · $49,436 | — | 12 |
Insider filings — SLATTERY JOSEPH P
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 5,200 @ $21.80 | EDGAR |
| 2026-06-18 | 4 | ImageneBio, Inc. (IMA) | Grant/award (A): 15,600 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | CVRx, Inc. (CVRX) | Grant/award (A): 8,720 @ $0 · Grant/award (A): 11,182 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | ImageneBio, Inc. (IMA) | Purchase (P): 16,000 @ $5.99 | EDGAR |
| 2025-12-22 | 4 | ImageneBio, Inc. (IMA) | Grant/award (A): 31,200 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | CVRx, Inc. (CVRX) | Grant/award (A): 19,554 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4 | Morphic Holding, Inc. (MORF) | Disposition to issuer (D): 9,066 · Disposition to issuer (D): 24,000 (derivative) · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 9,615 (derivative) · Disposition to issuer (D): 17,550 (derivative) · Disposition to issuer (D): 12,535 (derivative) · +1 more | EDGAR |
| 2024-08-15 | 4 | CVRx, Inc. (CVRX) | Purchase (P): 3,000 @ $8.10 | EDGAR |
| 2024-08-08 | 4 | CVRx, Inc. (CVRX) | Purchase (P): 3,000 @ $8.24 | EDGAR |
| 2024-08-06 | 4 | CVRx, Inc. (CVRX) | Purchase (P): 2,500 @ $9.09 | EDGAR |
| 2024-06-07 | 4/A | CVRx, Inc. (CVRX) | Grant/award (A): 27,250 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | CVRx, Inc. (CVRX) | Grant/award (A): 20,961 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 23,168 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2024-01-02 | 4 | CVRx, Inc. (CVRX) | Option exercise (M): 224 @ $0.24 · Option exercise (M): 1,456 @ $0.24 · Option exercise (M): 174 @ $1.19 · Option exercise (M): 96 @ $3.96 · Option exercise (M): 224 (derivative) @ $0 · Option exercise (M): 1,456 (derivative) @ $0 · +2 more | EDGAR |
| 2023-11-14 | 4 | Morphic Holding, Inc. (MORF) | Purchase (P): 2,400 @ $20.60 | EDGAR |
| 2023-06-07 | 4 | CVRx, Inc. (CVRX) | Grant/award (A): 12,012 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 12,535 (derivative) @ $0 | EDGAR |
| 2023-04-04 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 25,200 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 17,550 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | CVRx, Inc. (CVRX) | Grant/award (A): 26,985 (derivative) @ $0 | EDGAR |
| 2022-04-29 | 4/A | Morphic Holding, Inc. (MORF) | Grant/award (A): 9,615 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | CVRx, Inc. (CVRX) | Option exercise (M): 2,149 @ $0.24 · Option exercise (M): 3,917 @ $0.24 · Option exercise (M): 316 @ $0.24 · Option exercise (M): 316 @ $0.24 · Option exercise (M): 2,528 @ $0.24 · Option exercise (M): 189 @ $0.24 · +18 more | EDGAR |
| 2021-12-02 | 4 | CVRx, Inc. (CVRX) | Option exercise (M): 3,000 @ $0.24 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | CVRx, Inc. (CVRX) | Grant/award (A): 5,555 @ $18 | EDGAR |
| 2021-07-01 | 4 | CVRx, Inc. (CVRX) | Grant/award (A): 10,382 (derivative) @ $0 · Grant/award (A): 9,100 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-04-05 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2020-12-09 | 4 | Replimune Group, Inc. (REPL) | Option exercise (M): 5,200 @ $3.30 · Sale (S): 5,200 @ $46 · Option exercise (M): 5,200 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1246530 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs